Skip to main content
Sharp Therapeutics Corp. logo

Sharp Therapeutics Corp. — Investor Relations & Filings

Ticker · SHRX ISIN · CA8200092077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 128 across all filing types
Latest filing 2024-12-21 M&A Activity
Country CA Canada
Listing TSXV SHRX

About Sharp Therapeutics Corp.

https://sharptx.com/

Sharp Therapeutics Corp. is a preclinical-stage drug discovery company developing small molecule therapeutics for hereditary disorders. The core business involves leveraging its proprietary Disco(tm) platform, which integrates high-speed laboratory automation with advanced computational methods, including molecular-physics and mathematical modeling, to rapidly identify small molecules that correct protein defects. This approach is designed to deliver first-choice oral medicines for genetic diseases, offering advantages over traditional biologics. Sharp focuses on monogenic diseases to utilize an accelerated and de-risked clinical development path. Current lead programs address high unmet needs in Gaucher Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C.

Recent filings

Filing Released Lang Actions
Other material contracts - English.pdf
M&A Activity Classification · 1% confidence The document is a definitive Merger Agreement detailing the terms and conditions for merging SEL AcquisitionCo Inc. with and into Sharp Edge Labs, Inc. It outlines the merger structure, treatment of shares, governance post-merger, and filing requirements under Delaware law. This falls squarely under announcements and documents related to merger proposals or takeover bids, which corresponds to M&A Activity (Code: TAR).
2024-12-21 English
Other material contracts - English.pdf
Regulatory Filings Classification · 0% confidence The document is an amendment to a private license agreement between Carnegie Mellon University and Sharp Edge Labs. It is not an annual or interim report, earnings release, board change, share issue, proxy statement, or any of the specified categories. It is essentially a contractual amendment disclosure and does not fit the specialized filing definitions, so it defaults to the fallback category for miscellaneous regulatory filings.
2024-12-21 English
Other material contracts - English.pdf
Regulatory Filings Classification · 0% confidence The document is a private Business Consultant Agreement between Sharp Edge Labs, Inc. and an individual consultant, detailing services, terms, payment and confidentiality. It is a contract rather than a regulatory disclosure, financial report, management announcement, or shareholder communication. None of the specific filing categories (e.g., Annual/Interim Report, Earnings Release, Proxy Statement, Board Change, etc.) match a private service agreement. Therefore, under the fallback rule for miscellaneous filings, it should be classified as a Regulatory Filing (RNS).
2024-12-21 English
Other material contracts - English.pdf
M&A Activity Classification · 1% confidence The document is a legal Sponsorship Agreement dated December 10, 2024 among a sponsor, the target (SEL), and the resulting issuer (EVP Capital) relating to a reverse triangular merger transaction under TSX Venture Exchange rules. It details due diligence, sponsorship duties, fees, covenants, and definitions in support of the Transaction (merger). It is not a financial report, earnings release, or management announcement, but is directly tied to M&A activities. Therefore, this falls under M&A Activity.
2024-12-21 English
Other material contracts - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a private letter agreement between STX Partners, LLC and Sharp Edge Labs, Inc. that confirms STX’s commitment to participate in a common stock financing round and exercise warrants, including terms for funding and share issuance. This clearly relates to financing activities and changes to the company’s capital structure rather than a formal regulatory filing, earnings release, or management report. Therefore, it best fits the “Capital/Financing Update” category (CAP).
2024-12-21 English
Other material contracts - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a legally binding Note Purchase Agreement for a 2023 Bridge Round financing, detailing convertible note issuance, closing terms, representations, and covenants among the company and investors. It is not an earnings release, annual report, or management discussion; rather, it documents a capital-raising transaction. Therefore, it falls under the Capital/Financing Update category.
2024-12-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.